Kanthi Lab

#COVID-19 Update

COVID-19 critical illness is marked by inflammation and blood clots. We are partnering with our good friends in Dr. Jason Knight's lab to find innovative ways to diagnose, and treat COVID. We're making all of our data publicly available.

Here's what we are working on together now:

1. Mechanistic studies - What does Coronavirus do to people?

(1) We discovered a COVID blood neutrophil biosignature that tracks with severity of COVID-19, and blood clots. See our research featured on the cover of JCI Insight: Neutrophil extracellular traps in COVID-19

(2) We've found a completely new way that blood clotting can occur in COVID-19, by antibodies generated during the infection. Finding a way to break this cycle of clotting may help reduce this highly morbid condition.

We are grateful for support from the Frankel Cardiovascular Center for supporting this research with a COVID Ignitor Award!

2. Started a COVID Clinical Trial to Find Safe, Effective Treatments for COVID

We've advanced our discoveries above and started a randomized, clinical trial to test whether dipyridamole, an old drug can treat COVID and prevent its potentially disastrous consequences.


If this treatment works, it could reduce the COVID respiratory complications that make people critically ill. Click here to read details about the DICER trial


Thanks to Dr. Chuck Burant and the Taubman Medical Research Institute for their "soup to nuts" support of this clinical trial!

Yogen Kanthi, MDAssistant ProfessorCardiovascular MedicineVascular Medicine

Dr. Kanthi has been named as a Lasker Investigator at the NIH!

The Kanthi Lab is moving to the National Heart, Lung and Blood Institute of the NIH.

We are excited to continue our collaborations with friends at the University of Michigan, and build a translational vascular medicine research program in the unique environment of the NIH!

What we did in the pre-COVID era (and hope to do again)....

The Kanthi laboratory studies the biology of venous diseases, including deep vein thrombosis (DVT), which occurs when patients develop potentially fatal blood clots in the deep veins of the legs and arms; and vascular bypass graft failure, which occurs when veins are used as bypass grafts to restore blood flow to tissue around arterial blockages.

Our lab is interested in the molecular mechanisms that lead to venous thrombosis and vein graft disease, and in developing novel therapies directed against these widely prevalent and morbid vascular diseases. Currently, our research is focused on endogenous, protective molecules at the intersection of inflammation and thrombosis, which can be harnessed to predict vascular disease and develop new therapeutics.

Dr. Kanthi is a board-certified in cardiovascular medicine. His clinical practice is focused on cardiology and vascular medicine.

University of Michigan Physician Profile

Follow Dr. Kanthi on Twitter

Research Opportunities

The Kanthi lab is actively seeking enthusiastic and motivated postdoctoral research fellows and graduate students.